AGI 5198 - IDH-C35
Axon 2122
CAS [1355326-35-0]
MF C27H31FN4O2MW 462.56
- Purity:100%
- Soluble in DMSO
Description
Potent inhibitor of mutant isocitrate dehydrogenase 1 (IDH1); selective for IDH1 R132H and R132C mutants in vitro with IC50 values of 0.07 and 0.16 µM, respectively; it delays growth and promotes differentiation of glioma cells.
KEYWORDS: AGI 5198 | supplier | IDH1 inhibitor | IDH-C35 | CAS [1355326-35-0] | Isocitrate | IDH | Inhibitor | Enzymes
| D Rohle et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science, 2013, 340(6132), 626-630. |
| FE Garrett-Bakelman and AM Melnick. Differentiation therapy for IDH1/2 mutant malignancies. Cell Res. 2013, 23, 975–977. |
- Certificate of Analysis
- Material Safety Data Sheet
Chemical name
N-cyclohexyl-2-(N-(3-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido)-2-o-tolylacetamide
Parent CAS No.
[1355326-35-0]
Axon Medchem的业务之一，是独有的Axon Ligands配体库，在世界范围内，被认为是药物研发的标准。这其中，针对850余种生物靶标（包括细胞信号、基因转录、凋亡、细胞周期调控、CNS等），Axon Medchem拥有多达2000余种小分子抑制剂或调节剂。除了配体库，Axon Medchem还是欧洲著名的CRO公司，主要针对生物活性分子和药物类似分子展开合成及协议开发工作，在过去的10年中，Axon Medchem已经发现了多种潜在药物分子，并在生物医药界享有一定的声誉。
暂无问答
本网站将在规定时间内给予删除等相关处理。
